Skip to main content
SpringerLink
Log in

Traditional Herbal Medicines, Bioactive Compounds, and Plant Products as Therapeutic Approach Against Interstitial Lung Disease

  • Chapter
  • First Online:
Genetic Manipulation of Secondary Metabolites in Medicinal Plant

Part of the book series: Interdisciplinary Biotechnological Advances ((IBA))

  • 137 Accesses

Abstract

Interstitial lung disease (ILD) encompasses a diverse range of respiratory disorders characterized by lung tissue inflammation and fibrosis. Its development can be influenced by multiple factors, and currently, there is no known cure for this condition. Despite advancements in medical treatments, ILD poses a significant health challenge with limited therapeutic options and varying outcomes. While synthetic drugs targeting specific pathways involved in ILD development are available to alleviate symptoms and slow disease progression, their usage has been associated with various side effects. It has been widely recognized for decades that medicinal plants and their compounds have been utilized worldwide in natural remedies for treating various diseases. This review article focuses on exploring the effects of different traditional herbal medicines, plant extracts, and their bioactive compounds. Specifically, it examines traditional Chinese herbal prescriptions, individual Chinese herbs containing bioactive compounds, and additional plant extracts that demonstrate prophylactic and therapeutic properties against ILD. These natural alternatives hold potential as substitutes for synthetic drugs and may help mitigate the side effects associated with their use in ILD treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abbafati C, Machado D, Cislaghi B, Salman O, Karanikolos M, McKee M, Abbas K, Brady O, Larson H, Trias-Llimós S et al (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet 396:1204–1222

    Article  Google Scholar 

  • Bagnato G, Harari S (2015) Cellular interactions in the pathogenesis of interstitial lung diseases. Eur Respir Rev 24:102–114

    Article  Google Scholar 

  • Bahri S, Ali RB, Abidi A, Jameleddine S (2017) The efficacy of plant extract and bioactive compounds approaches in the treatment of pulmonary fibrosis: a systematic review. Biomed Pharmacother 93:666–673

    Article  CAS  Google Scholar 

  • Behr J (2012) Prednisone, azathioprine, and n-acetylcysteine for pulmonary fibrosis. N Engl J Med 367:869

    Article  CAS  Google Scholar 

  • Boots AW, Drent M, de Boer VC, Bast A, Haenen GR (2011) Quercetin reduces markers of oxidative stress and inflammation in sarcoidosis. Clin Nutr 30:506–512

    Article  CAS  Google Scholar 

  • Choi WI, Dauti S, Kim HJ, Park SH, Park JS, Lee CW (2018) Risk factors for interstitial lung disease: a 9-year nationwide population-based study. BMC Pulm Med 18:1–7

    Article  Google Scholar 

  • Chu H, Shi Y, Jiang S, Zhong Q, Zhao Y, Liu Q, Ma Y, Shi X, Ding W, Zhou X et al (2017) Treatment effects of the traditional chinese medicine shenks in bleomycin-induced lung fibrosis through regulation of tgf-beta/smad3 signaling and oxidative stress. Sci Rep 7:2252

    Article  Google Scholar 

  • Coultas DB, Zumwalt RE, Black WC, Sobonya RE (1994) The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 150:967–972

    Article  CAS  Google Scholar 

  • Cui Y, Xin H, Tao Y, Mei L, Wang Z (2021) Arenaria kansuensis attenuates pulmonary fibrosis in mice via the activation of Nrf2 pathway and the inhibition of NF-kB/TGF-beta1/Smad2/3 pathway. Phytotherapy Research 35(2):974–986

    Article  CAS  Google Scholar 

  • Delmonico MJ, Harris TB, Lee JS, Visser M, Nevitt M, Kritchevsky SB, Tylavsky FA, Newman AB, Health Aging and Body Composition Study (2007) Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women. J Am Geriatr Soc 55:769–774

    Article  Google Scholar 

  • Delmonico MJ, Harris TB, Visser M, Park SW, Conroy MB, Velasquez-Mieyer P, Boudreau R, Manini TM, Nevitt M, Newman AB, Goodpaster BH (2009) Longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am J Clin Nutr 90:1579–1585

    Article  CAS  Google Scholar 

  • Dong SH, Liu YW, Wei F, Tan HZ, Han ZD (2017) Asiatic acid ameliorates pulmonary fibrosis induced by bleomycin (blm) via suppressing pro-fibrotic and inflammatory signaling pathways. Biomed Pharmacother 89:1297–1309

    Article  CAS  Google Scholar 

  • Dudala SS, Venkateswarulu T, Kancharla SC, Kodali VP, Babu DJ (2021) A review on importance of bioactive compounds of medicinal plants in treating idiopathic pulmonary fibrosis (special emphasis on isoquinoline alkaloids). Fut J Pharmaceut Sci 7:1–20

    Google Scholar 

  • George PM, Patterson CM, Reed AK, Thillai M (2019) Lung transplantation for idiopathic pulmonary fibrosis. Lancet Respir Med 7:271–282

    Article  Google Scholar 

  • Gong LK, Li XH, Wang H, Zhang L, Chen FP, Cai Y, Qi XM, Liu LL, Liu YZ, Wu XF et al (2005) Effect of Feitai on bleomycin-induced pulmonary fibrosis in rats. J Ethnopharmacol 96:537–544

    Article  Google Scholar 

  • Guo Z, Li S, Zhang N, Kang Q, Zhai H (2020) Schisandra inhibit bleomycin-induced idiopathic pulmonary fibrosis in rats via suppressing m2 macrophage polarization. Biomed Res Int 2020:5137349

    Article  Google Scholar 

  • Harari S, Raghu G, Caminati A, Cruciani M, Franchini M, Mannucci P (2020) Fibrotic interstitial lung diseases and air pollution: a systematic literature review. Eur Respir Rev 29:200093

    Article  Google Scholar 

  • Hay ED (1991) Collagen and other matrix glycoproteins in embryogenesis. In: Cell biology of extracellular matrix, 2nd edn. Plenum Press, New York, pp 419–462

    Chapter  Google Scholar 

  • He H, Tang H, Gao L, Wu Y, Feng Z, Lin H, Wu T (2015) Tanshinone a attenuates bleomycin-induced pulmonary fibrosis in rats. Mol Med Rep 11:4190–4196

    Article  CAS  Google Scholar 

  • He Z, Hu Y, Niu Z, Zhong K, Liu T, Yang M, Ji L, Hu W (2022) A review of pharmacokinetic and pharmacological properties of asiaticoside, a major active constituent of Centella asiatica (l.) urb. J Ethnopharmacol 302:115865

    Article  Google Scholar 

  • Higashiyama H, Yoshimoto D, Kaise T, Matsubara S, Fujiwara M, Kikkawa H, Asano S, Kinoshita M (2007) Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis. Exp Mol Pathol 83:39–46

    Article  CAS  Google Scholar 

  • Hosseini S, Imenshahidi M, Hosseinzadeh H, Karimi G (2018) Effects of plant extracts and bioactive compounds on attenuation of bleomycin-induced pulmonary fibrosis. Biomed Pharmacother 107:1454–1465

    Article  CAS  Google Scholar 

  • Hosseini SA, Zahedipour F, Sathyapalan T, Jamialahmadi T, Sahebkar A (2021) Pulmonary fibrosis: therapeutic and mechanistic insights into the role of phytochemicals. Biofactors 47:250–269

    Article  CAS  Google Scholar 

  • Huo R, Huang X, Yang Y, Yang Y, Lin J (2023) Potential of resveratrol in the treatment of interstitial lung disease. Front Pharmacol 14:1139460

    Article  CAS  Google Scholar 

  • Ji Y, Wang T, Wei ZF, Lu GX, Xia YF, Dai Y et al (2013) Paeoniflorin, the main active constituent of Paeonia lactiflora roots, attenuates bleomycin-induced pulmonary fibrosis in mice by suppressing the synthesis of type I collagen. J Ethnopharmacol 149:825–832

    Article  CAS  Google Scholar 

  • Jin M, Wu Y, Wang L, Zang B, Tan L (2016) Hydroxysafflor yellow an attenuates bleomycin-induced pulmonary fibrosis in mice. Phytother Res 30:577–587

    Article  CAS  Google Scholar 

  • Kekevian A, Gershwin ME, Chang C (2014) Diagnosis and classification of idiopathic pulmonary fibrosis. Autoimmun Rev 13:508–512

    Article  CAS  Google Scholar 

  • King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370:2083–2092

    Article  Google Scholar 

  • Krishna G, Liu K, Shigemitsu H, Gao M, Raffin TA, Rosen GD (2001) Pg490-88, a derivative of triptolide, blocks bleomycin-induced lung fibrosis. Am J Pathol 158:997–1004

    Article  CAS  Google Scholar 

  • Kulkarni AV, Hanchanale P, Prakash V, Kalal C, Sharma M, Kumar K et al (2022) Tinospora Cordifolia (G iloy)–Induced Liver Injury During the COVID-19 Pandemic—Multicenter Nationwide Study From India. Hepatology Communications 6(6):1289–1300

    Google Scholar 

  • Kuwano K, Kunitake R, Kawasaki M, Nomoto Y, Hagimoto N, Nakanishi Y, Hara N (1996) P21waf1/cip1/sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 154:477–483

    Article  CAS  Google Scholar 

  • Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, Kng TE Jr, Collard HR (2011) Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184:1390–1394

    Article  Google Scholar 

  • Leslie K (2009) My approach to interstitial lung disease using clinical, radiological and histopathological patterns. J Clin Pathol 62:387–401

    Article  CAS  Google Scholar 

  • Li M, Li Y, Li J, Zhao P, Bai Y, Feng S, Liu X, Wang Y, Bian Q, Li J (2017) Long-term effects of TCM Yangqing Kangxian formula on bleomycin-induced pulmonary fibrosis in rats via regulating nuclear factor-κb signaling. Evid Based Complement Alternat Med 2017:2089027

    Article  Google Scholar 

  • Li Y, Zhu W, He H, Garov YA, Bai L, Zhang L, Wang J, Wang J, Zhou X (2021) Efficacy and safety of Tripterygium Wilfordii Hook. F for connective tissue disease-associated interstitial lung disease: a systematic review and meta-analysis. Front Pharmacol 12:691031

    Article  Google Scholar 

  • Li J, Jia B, He J, Xing B, Zhang Y (2022) The anti-pulmonary fibrosis of Salvia miltiorrhiza Bunge: a systematic review. TMR Mod Herb Med 5:12

    Article  Google Scholar 

  • Liu M, Liao J, Wang W, Lijian P, Lv X (2018) Treatment of idiopathic pulmonary fibrosis according to treating yangming meridian for flaccidity. Chinese Archives of Aditional Chinese Medicine 36(06):1414–1416

    Google Scholar 

  • Mizuguchi S, Takemura S, Minamiyama Y, Kodai S, Tsukioka T, Inoue K, Okada S, Suehiro S (2006) S-allyl cysteine attenuated ccl4-induced oxidative stress and pulmonary fibrosis in rats. Biofactors 26:81–92

    Article  CAS  Google Scholar 

  • Morimoto T, Azuma A, Abe S, Usuki J, Kudoh S, Sugisaki K, Oritsu M, Nukiwa T (2008) Epidemiology of sarcoidosis in Japan. Eur Respir J 31:372–379

    Article  CAS  Google Scholar 

  • Morisset J, Lee JS (2019) New trajectories in the treatment of interstitial lung disease: treat the disease or treat the underlying pattern? Curr Opin Pulm Med 25:442–449

    Article  Google Scholar 

  • Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS (2001) Sarcopenia. J Lab Clin Med 137:231–243

    Article  CAS  Google Scholar 

  • Murthy P, Shaibie NA, Lim CL, Ling APK, Chye SM, Koh RY (2022) An overview of herbal medicines for idiopathic pulmonary fibrosis. PRO 10:1131

    CAS  Google Scholar 

  • Noth I, Anstrom KJ, Calvert SB, De Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA (2012) A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 186:88–95

    Article  CAS  Google Scholar 

  • Qu Y, Zhang G, Ji Y, Zhua H, Lv C, Jiang W (2016) Protecive role of gambogic acid in experimental pulmonary fibrosis in vitro and in vivo. Phytomedicine 23:350–358

    Article  CAS  Google Scholar 

  • Richeldi L, Du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370:2071–2082

    Article  Google Scholar 

  • Schamberger AC, Schiller HB, Fernandez IE, Sterclova M, Heinzelmann K, Hennen E, Hatz R, Behr J, Vašáková M, Mann M et al (2016) Glutathione peroxidase 3 localizes to the epithelial lining fluid and the extracellular matrix in interstitial lung disease. Sci Rep 6:1–15

    Article  Google Scholar 

  • Selman M, Thannickal VJ, Pardo A, Zisman DA, Martinez FJ, Lynch JP (2004) Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs 64:405–430

    Article  CAS  Google Scholar 

  • Shao R, Wang FJ, Lyu M, Yang J, Zhang P, Zhu Y (2019) Ability to suppress TGF-β-activated myofibroblast differentiation distinguishes the anti-pulmonary fibrosis efficacy of two Danshen-containing Chinese herbal medicine prescriptions. Front Pharmacol 10:412

    Article  CAS  Google Scholar 

  • Sijia G, Yalin S, Jihong F, Shuang L, Yuechuan L, Min L, Luqing W, Xian Z, Hui X, Zengtao S (2020) Effects of qizhukangxian granules on idiopathic pulmonary fibrosis: a randomized, double blind, placebo-controlled and multicenter clinical pilot trial. J Tradit Chin Med 40:674

    Google Scholar 

  • Singh S, Collins BF, Sharma BB, Joshi JM, Talwar D, Katiyar S, Singh N, Ho L, Samaria JK, Bhattacharya P et al (2017) Interstitial lung disease in India. Results of a prospective registry. Am J Respir Crit Care Med 195:801–813

    Article  Google Scholar 

  • Tahir I, Khan MR, Shah NA, Aftab M (2016) Evaluation of phytochemicals, antioxidant activity and amelioration of pulmonary fibrosis with Phyllanthus emblica leaves. BMC complementary and alternative medicine 16:1–12

    Article  Google Scholar 

  • Tao L, Cao J, Wei W, Xie H, Zhang M, Zhang C (2017) Protective role of rhapontin in experimental pulmonary fibrosis in vitro and in vivo. Int Immunopharmacol 47:38–46

    Article  CAS  Google Scholar 

  • Thierry F, Handel I, Hammond G, King LG, Corcoran BM, Schwarz T (2017) Further characterization of computed tomographic and clinical features for staging and prognosis of idiopathic pulmonary fibrosis in west highland white terriers. Vet Radiol Ultrasound 58:381–388

    Article  Google Scholar 

  • Tian S, Cao WF, Zhang YY, Wu Q (2019) Effects of Yiqi Huayu Hutan decoction on pulmonary fibrosis in rats and its mechanism. Zhongguo Ying Yong Sheng Li Xue Za Zhi 35:101–106

    Google Scholar 

  • Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU et al (2013) An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188:733–748

    Article  Google Scholar 

  • Tsukioka T, Takemura S, Minamiyama Y, Mizuguchi S, Toda M, Okada S (2017) Attenuation of bleomycin-induced pulmonary fibrosis in rats with s-allyl cysteine. Molecules 22:543

    Article  Google Scholar 

  • Van Wyk B, Wink M (2004) Medicinal plants of the world. Briza Publications, Pretoria, South Africa

    Google Scholar 

  • Wang D, Gong L, Li Z, Chen H, Xu M, Rong R, Zhang Y, Zhu Q (2021a) Antifibrotic effect of Gancao Ganjiang decoction is mediated by PD-1/TGF-β1/IL-17A pathway in bleomycin-induced idiopathic pulmonary fibrosis. J Ethnopharmacol 281:114522

    Article  CAS  Google Scholar 

  • Wang J, Wang H, Fang F, Fang C, Wang S, Lu C, Liu N (2021b) Dang-Gui Buxue Tang ameliorates bleomycin-induced pulmonary fibrosis by suppressing the TLR4/NLRP3 signaling pathway in rats. Evid Based Complement Alternat Med 2021:8030143

    Google Scholar 

  • Xaubet A, Ancochea J, Molina-Molina M (2017) Idiopathic pulmonary fibrosis. Med Clín 148:170–175

    Google Scholar 

  • Xia X, Dai C, Yu H, Huang X, Chen A, Tan Y, Wang L (2018) Asiatic acid prevents the development of interstitial lung disease in a hypochlorous acid-induced mouse model of scleroderma. Oncol Lett 15:8711–8716

    Google Scholar 

  • Xiao J, Tian B, Xie B, Yang E, Shi J, Sun Z (2010) Supercritical fluid extraction and identification of isoquinoline alkaloids from leaves of Nelumbo nucifera Gaertn. Eur Food Res Technol 231:407–414

    Article  CAS  Google Scholar 

  • Yang Y, Huang Y, Huang C, Lv X, Liu L, Wang Y, Li J (2012) Antifibrosis effects of triterpene acids of Eriobotrya japonica (Thunb.) Lindl. leaf in a rat model of bleomycin-induced pulmonary fibrosis. Journal of Pharmacy and Pharmacology 64(12):1751–1760

    Article  CAS  Google Scholar 

  • Yang L, Wang Q, Hou Y, Zhao J, Li M, Xu D, Zeng X (2020) The Chinese herb Tripterygium Wilfordii Hook Ffor the treatment of systemic sclerosis-associated interstitial lung disease: data from a Chinese Eustar Center. Clin Rheumatol 39:813–821

    Article  Google Scholar 

  • Yen FL, Wu TH, Liao CW, Lin CC (2007) A kampo medicine, Yin-Chiao-san, prevents bleomycin-induced pulmonary injury in rats. Phytother Res 21:251–258

    Article  Google Scholar 

  • Yin JN, Li YN, Gao Y, Li SB, Li JD (2015) Andrographolide plays an important role in bleomycin-induced pulmonary fibrosis treatment. Int J Clin Exp Med 8:12374

    CAS  Google Scholar 

  • Yu X, Zhang Y, Yang X, Zhang X, Wang X, Liu X, Yan Y (2018) The influence of BuqiHuoxueTongluo formula on histopathology and pulmonary function test in bleomycin-induced idiopathic pulmonary fibrosis in rats. Evid Based Complement Alternat Med 2018:8903021

    Article  Google Scholar 

  • Zhang Y, Lu P, Qin H, Zhang Y, Sun X, Song X, Liu J, Peng H, Liu Y, Nwafor EO et al (2021) Traditional Chinese medicine combined with pulmonary drug delivery system and idiopathic pulmonary fibrosis: rationale and therapeutic potential. Biomed Pharmacother 133:111072

    Article  CAS  Google Scholar 

  • Zhao L, Wang X, Chang Q, Xu J, Huang Y, Guo Q et al (2010) Neferine, a bisbenzylisoquinline alkaloid attenuates bleomycin-induced pulmonary fibrosis. European journal of pharmacology 627(1-3):304–312

    Article  CAS  Google Scholar 

  • Zhou XM, Huang MM, He CC, Li JX (2009) Inhibitory effects of citrus extracts on the experimental pulmonary fibrosis. Journal of ethnopharmacology 126(1):143–148

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pulmonary Medicine, All India Institute of Medical Sciences, Patna, Bihar, India

    Lovely Sinha & Saurabh Karmakar

Authors
  1. Lovely Sinha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Saurabh Karmakar
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Plant Breeding and Genetics, Bihar Agricultural University, Sabour, Bihar, India

    Ravi Singh

  2. Department of Biotechnology, Central University of South Bihar, Gaya, Bihar, India

    Nitish Kumar

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sinha, L., Karmakar, S. (2023). Traditional Herbal Medicines, Bioactive Compounds, and Plant Products as Therapeutic Approach Against Interstitial Lung Disease. In: Singh, R., Kumar, N. (eds) Genetic Manipulation of Secondary Metabolites in Medicinal Plant. Interdisciplinary Biotechnological Advances. Springer, Singapore. https://doi.org/10.1007/978-981-99-4939-7_15

Download citation

Publish with us

Policies and ethics

Search

Navigation